[go: up one dir, main page]

NO20061537L - Fremgangsmate for a levere legemidler til hjernen - Google Patents

Fremgangsmate for a levere legemidler til hjernen

Info

Publication number
NO20061537L
NO20061537L NO20061537A NO20061537A NO20061537L NO 20061537 L NO20061537 L NO 20061537L NO 20061537 A NO20061537 A NO 20061537A NO 20061537 A NO20061537 A NO 20061537A NO 20061537 L NO20061537 L NO 20061537L
Authority
NO
Norway
Prior art keywords
brain
dispersion
particles
pharmaceutical preparation
mammal
Prior art date
Application number
NO20061537A
Other languages
English (en)
Norwegian (no)
Inventor
James E Kipp
Barrett E Rabinow
Howard Gendelman
Original Assignee
Univ Nebraska By And Behalf Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska By And Behalf Of filed Critical Univ Nebraska By And Behalf Of
Publication of NO20061537L publication Critical patent/NO20061537L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061537A 2003-06-24 2006-04-04 Fremgangsmate for a levere legemidler til hjernen NO20061537L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48209603P 2003-06-24 2003-06-24
PCT/US2004/018850 WO2004112747A2 (fr) 2003-06-24 2004-06-15 Methode d'administration de medicaments au cerveau

Publications (1)

Publication Number Publication Date
NO20061537L true NO20061537L (no) 2006-04-04

Family

ID=33539336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061537A NO20061537L (no) 2003-06-24 2006-04-04 Fremgangsmate for a levere legemidler til hjernen

Country Status (8)

Country Link
US (1) US9044381B2 (fr)
EP (1) EP1663158A2 (fr)
AU (1) AU2004249172A1 (fr)
BR (1) BRPI0414970A2 (fr)
CA (1) CA2540695A1 (fr)
NO (1) NO20061537L (fr)
WO (1) WO2004112747A2 (fr)
ZA (1) ZA200603062B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026611A2 (fr) 2001-09-26 2003-04-03 Baxter International Inc. Preparation de nanoparticules submicroniques par dispersion et elimination d'un solvant ou d'une phase liquide
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
EP1663158A2 (fr) 2003-06-24 2006-06-07 Baxter International Inc. Methode d'administration de medicaments au cerveau
CN1913871A (zh) * 2004-01-29 2007-02-14 巴克斯特国际公司 用于提高中枢神经系统投递的抗－逆转录病毒药剂的纳米悬浮液
RU2006146985A (ru) * 2004-05-28 2008-07-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
BRPI0510271A (pt) 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
EP2279726A3 (fr) 2005-05-26 2012-06-20 Biorest Ltd. Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine
US20080274202A1 (en) * 2005-08-01 2008-11-06 Kraig Richard P Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents
KR100762954B1 (ko) * 2006-01-26 2007-10-04 나재운 항암제가 봉입된, 소수성 담즙산이 결합된 친수성 키토산올리고당 나노입자 및 그 제조방법
KR100785656B1 (ko) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
EP2170283B1 (fr) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation de particules de peptide ou de protéine submicroniques stables par congélation de film mince
BRPI0909780B1 (pt) * 2008-03-05 2022-05-03 Baxter International Inc Suspensão contendo uma partícula com superfície modificada, composição farmacêutica compreendendo a referida suspensão, método para aprimorar a absorção celular de um agente ativo, uso de partículas com superfície modificada, e método de preparação de uma partícula com superfície modificada
US8779094B2 (en) * 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
WO2010068899A1 (fr) 2008-12-12 2010-06-17 Creighton University Nanoparticules comprenant des combinaisons d'agents antirétroviraux, et utilisations de celles-ci
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
DK2921486T3 (da) 2009-08-07 2017-11-13 American Life Science Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme
WO2011119487A2 (fr) * 2010-03-22 2011-09-29 Genentech, Inc. Compositions et procédés utiles pour stabiliser les formulations contenant des protéines
JP2013542945A (ja) * 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
WO2012138003A1 (fr) * 2011-04-08 2012-10-11 경북대학교 산학협력단 Utilisations d'un dérivé d'héparine-acide biliaire désulfaté pour la prévention et le traitement de maladies inflammatoires
DE102012009570A1 (de) 2012-05-09 2013-11-14 Naum Goldstein Komposition für nasale Anwendung
DE102012015248A1 (de) * 2012-08-05 2014-02-06 Naum Goldstein Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP3203995A4 (fr) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
EP3737359A4 (fr) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska Promédicaments antiviraux et formulations de ceux-ci
CA3132832A1 (fr) 2018-04-09 2019-10-17 Howard E. Gendelman Promedicaments antiviraux et formulations de ceux-ci
JP2023509800A (ja) 2020-01-10 2023-03-09 コンシナンス セラピューティクス， インコーポレイテッド 薬物の治療的組み合わせ及びそれらの使用方法
WO2021148990A1 (fr) * 2020-01-23 2021-07-29 Axcess Limited Absorption cellulaire
CN118215738A (zh) 2021-07-22 2024-06-18 加利福尼亚大学董事会 使用纯化的人rna编辑酶的组合物和方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655801C2 (de) * 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
DE2656317C2 (de) * 1976-12-11 1986-06-19 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten
DE2656746C2 (de) * 1976-12-15 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verwendung von beladenen Erythrozyten
US4670185A (en) * 1982-07-19 1987-06-02 Lion Corporation Aqueous vesicle dispersion having surface charge
JPS60150826A (ja) 1984-01-18 1985-08-08 Lion Corp 表面電荷をもつベシクル分散液
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5614652A (en) 1991-01-07 1997-03-25 Syngenix Limited Particulates
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0663951T3 (da) * 1992-09-28 2002-09-30 Univ Brown Res Found Chitosan-matricer til indkapslede celler
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6331299B1 (en) * 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
JP5038552B2 (ja) 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達
JP2000514440A (ja) * 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー 遺伝子輸送システム
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
AU7133898A (en) 1997-04-18 1998-11-13 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
US20020068048A1 (en) 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO2000006244A2 (fr) * 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
WO2000064954A1 (fr) 1999-04-22 2000-11-02 Vanderbilt University Systeme d'encapsulation de polymeres facilitant l'angiogenese
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
CN1235567C (zh) 1999-09-09 2006-01-11 加利福尼亚大学董事会 将紫杉烷输送到正在生成的血管的阳离子性脂质体
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
GB0002856D0 (en) 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
JP4085231B2 (ja) * 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法
HK1048772A1 (zh) * 2000-02-28 2003-04-17 Genesegues, Inc. 纳米胶囊包封系统与方法
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
AU2001266272B2 (en) 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US6455073B1 (en) * 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
DE60138641D1 (de) * 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
BR0116377A (pt) 2000-12-22 2005-12-13 Baxter Int Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002060416A1 (fr) 2001-02-01 2002-08-08 Gendel Limited Systeme d'administration de polypeptide et leur procede de preparation
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6790455B2 (en) * 2001-09-14 2004-09-14 The Research Foundation At State University Of New York Cell delivery system comprising a fibrous matrix and cells
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
WO2004103348A2 (fr) * 2003-05-19 2004-12-02 Baxter International Inc. Preparations pharmaceutiques de petites particules d'anticonvulsivants et d'agents contre la demence et agents immmunosupresseurs
CA2528869A1 (fr) 2003-06-12 2004-12-23 Regents Of The University Of Minnesota Methode pour diriger des cellules sur des tissus ou des organes cibles
CA2529965C (fr) 2003-06-20 2011-01-25 Lipid Sciences, Inc. Particules virales modifiees possedant des proprietes immunogenes et une teneur limitee en lipides utiles pour traiter et prevenir des maladies infectieuses
EP1663158A2 (fr) 2003-06-24 2006-06-07 Baxter International Inc. Methode d'administration de medicaments au cerveau
US20050084456A1 (en) * 2003-10-21 2005-04-21 Liping Tang Functionalized particles
GB0329310D0 (en) 2003-12-18 2004-01-21 Univ Keele Method
CN1913871A (zh) 2004-01-29 2007-02-14 巴克斯特国际公司 用于提高中枢神经系统投递的抗－逆转录病毒药剂的纳米悬浮液
CA2788707C (fr) 2004-02-02 2014-02-25 Engeneic Molecular Delivery Pty Ltd. Compositions et procedes de liberation de medicaments in vitro et in vivo ciblee dans des cellules mammiferes par le biais de minicellules intactes derivees de bacteries
BRPI0510271A (pt) 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
JPWO2006080243A1 (ja) 2005-01-28 2008-06-19 コニカミノルタエムジー株式会社 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
JP5700909B2 (ja) 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
CN1772303A (zh) 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物

Also Published As

Publication number Publication date
EP1663158A2 (fr) 2006-06-07
US20050048002A1 (en) 2005-03-03
AU2004249172A1 (en) 2004-12-29
WO2004112747A2 (fr) 2004-12-29
WO2004112747A3 (fr) 2005-03-03
BRPI0414970A2 (pt) 2012-12-11
ZA200603062B (en) 2007-04-25
US9044381B2 (en) 2015-06-02
CA2540695A1 (fr) 2004-12-29

Similar Documents

Publication Publication Date Title
NO20061537L (no) Fremgangsmate for a levere legemidler til hjernen
WO2007124224A3 (fr) Procédé de délivrance de médicaments particulaires dans des tissus
Glavaski‐Joksimovic et al. Glial cell line‐derived neurotrophic factor–secreting genetically modified human bone marrow‐derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease
NZ620879A (en) A novel formulation of indomethacin
Li et al. Lactate‐Responsive Gene Editing to Synergistically Enhance Macrophage‐Mediated Cancer Immunotherapy
CN111328331A (zh) 用于将肠道中的抗生素抗性细菌去定植的组合物和方法
Solana‐Balaguer et al. Neuron‐derived extracellular vesicles contain synaptic proteins, promote spine formation, activate TrkB‐mediated signalling and preserve neuronal complexity
NZ710383A (en) A novel formulation of diclofenac
CA2876512A1 (fr) Cellules souches de type mesenchymateuses issues de cellules souches embryonnaires humaines, leurs procedes et leurs utilisations
WO2013022783A3 (fr) Formes de posologie orale contenant de la progestérone et procédés associés
CN113474448A (zh) 高复杂度合成肠道细菌群落
EP3580191A1 (fr) Ambroxol à isotope amélioré pour induction d'autophagie durable
JP2020534299A (ja) 神経学的状態を治療するための方法および改善された神経保護組成物
Kuan et al. New therapeutic approaches to Parkinson’s disease including neural transplants
De Lima et al. Contractile responses of proximal and distal trachea segments isolated from rats subjected to immunological stimulation: role of connective tissue mast cells
Chen et al. Customized Hydrogel System for the Spatiotemporal Sequential Treatment of Periodontitis Propelled by ZEB1
WO2006097725A3 (fr) Preparations pharmaceutiques comprenant des microparticules penetrant les neurones
Rashchupkin et al. Effect of M2 macrophage-derived soluble factors on proliferation and apoptosis of SH-SY5Y Cells
JP2025508836A (ja) 免疫系を調節するための組成物及び方法
EP2830641B1 (fr) Nouveaux extraits de valeriane et leurs utilisations
US20170095505A1 (en) Combination of xenon and an antioxidant to control a parkinson's disease-type neurodegenerative disease
JP2005508906A (ja) 抗炎症剤
WO2006030301A8 (fr) Composition pharmaceutique contenant du cilostazol, a base de particules d'une taille inferieure a 50 micrometres
Ravisankar Periyasamy et al. Neurochemical observations after the transplantation of human amniotic epithelial cells in 2, 4, 5-trihydroxyphenylethylamine (6-OHDA) induced Parkinsonism disease model in Wistar albino rats
CN104955442A (zh) 含维生素b12的药物组合物

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application